NRC FORM 591M PART 1
(10-2003)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE/LOCATION INSPECTED:	2. NRC/REGIONAL OFFICE
Cardiology Associates of Northwest Indiana, P.C. 9122 Columbia Avenue Munster, IN 46321	UNITED STATES NUCLEAR REGULATORY COMMISSION REGION III 2443 WARRENVILLE ROAD, SUITE 210 LISLE, IL 60532-4352

REPORT 2006-001

3. DOCKET NUMBER(S)	4. LICENSEE NUMBER(S)	5. DATE(S) OF INSPECTION
030-33827	13-26642-01	May 19, 2006

LICENSEE:

The inspection was an examination of the activities conducted under your license as they relate to radiation safety and to compliance with the Nuclear Regulatory Commission (NRC) rules and regulations and the conditions of your license. The inspection consisted of selective examinations of procedures and representative records, interviews with personnel, and observations by the inspector. The inspection findings are as follows:

☑ 1. Based on the inspection findings, no violations were identified.

☐ 2. Previous violation(s) closed.

☐ 3. The violation(s), specifically described to you by the inspector as non-cited violations, are not being cited because they were self-identified, non-repetitive, and corrective action was or is being taken, and the remaining criteria in the NRC Enforcement Policy, NUREG-1600, to exercise discretion, were satisfied.

_____ Non-Cited Violation(s) was/were discussed involving the following requirement(s) and Corrective Action(s):

☐ 4. During this inspection certain of your activities, as described below and/or attached, were in violation of NRC requirements and are being cited. This form is a NOTICE OF VIOLATION, which may be subject to posting in accordance with 10 CFR 19.11.

(Violations and Corrective Actions)

Licensee's Statement of Corrective Actions for Item 4, above.

I hereby state that, within 30 days, the actions described by me to the inspector will be taken to correct the violations identified. This statement of corrective actions is made in accordance with the requirements of 10 CFR 2.201 (corrective steps already taken, corrective steps which will be taken, date when full compliance will be achieved). I understand that no further written response to NRC will be required, unless specifically requested.

Title	Printed Name	Signature	Date
LICENSEE'S REPRESENTATIVE			
NRC INSPECTOR	Robert P. Hays		5/19/06

NRC FORM 591M PART 3
(10-2003)
10 CFR 2.201

U.S. NUCLEAR REGULATORY COMMISSION

Docket File Information
SAFETY INSPECTION REPORT AND COMPLIANCE INSPECTION

1. LICENSEE	2. NRC/REGIONAL OFFICE
Cardiology Associates of NW Indiana, P.C. REPORT NUMBER(S) 2006-001	Region III

3. DOCKET NUMBER(S)	4. LICENSE NUMBER(S)	5. DATE(S) OF INSPECTION
03033827	13-26642-01	May 19, 2006

6. INSPECTION PROCEDURES USED	7. INSPECTION FOCUS AREAS
87130	03.01 - 03.07

SUPPLEMENTAL INSPECTION INFORMATION

1. PROGRAM CODE(S)	2. PRIORITY	3. LICENSEE CONTACT	4. TELEPHONE NUMBER
02201	5	Anne Kurz, CNMT	219/934-4200

[X] Main Office Inspection — Next Inspection Date: May 2011

[ ] Field Office _____

[ ] Temporary Job Site _____

PROGRAM SCOPE

The licensee was a medical clinic located in Munster, IN, authorized by the license to use any byproduct material for medical use as needed permitted by 10 CFR 35.100 and 35.200, excluding xenon-133, generators, and aerosols at the address specified on the license. The nuclear medicine department was staffed with 3 full-time nuclear medicine technologists (NMTs) who routinely conduct an average of 14-16 cardiac studies, Monday through Friday, each week. The licensee received unit doses as ordered from a local nuclear pharmacy. All waste was held for decay-in-storage (DIS) or returned to the nuclear pharmacy as a limited quantity shipment. No change in RSO since the previous inspection.

Performance Observations

During the inspection, the licensee's NMTs demonstrated/discussed: (1) package check-in procedures and wipe test counting; (2) dosimetry; (3) dose calibrator checks; (4) security of license materials; (5) quarterly radiation safety program reviews; (6) radiopharmaceutical dosage prep and safe use; and (7) decontamination procedures.